MILAN--(BUSINESS WIRE)--Study will evaluate the effectiveness of PARAD+™ algorithm in minimizing inappropriate defibrillator shocks. Sorin Group, (Reuters Code: SORN.MI) (MIL:SRN), a global medical company and a leader in the treatment of cardiovascular diseases, announced today the first patient enrollment in its ISIS-ICD clinical trial. The primary objective of the study is to evaluate the percentage of patients implanted with an implantable cardioverter-defibrillator (ICD) featuring the Sorin PARAD+™ discrimination algorithm that are free from inappropriate ICD shocks over a one-year follow up. The first patient was enrolled by Mark Richards, PhD MD FACC, at The Toledo Hospital in Toledo, Ohio, USA.
